Tag: TECENTRIQ

Update on Genentech’s Tecentriq Plus Avastin

South San Francisco, CA  April 18, 2023 Press Release Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study   In the first-ever positive Phase III…

Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer

South San Francisco, CA  November 29, 2017 Genentech Press Release – Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00 Genentech,…